Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31074821 | 0.83 | TK1 (0.44) | TK1LMNAALBBLMTSHR | |
| SCHEMBL9060459 | 0.83 | TK1 (0.41) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL5036896 | 0.83 | TK1 (0.41) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL1490858 | 0.82 | TK1 (0.42) | TK1LMNAALBBLMTSHR | |
| SCHEMBL29474410 | 0.82 | TK1 (0.39) | TK1LMNAALBBLMTSHR | |
| SCHEMBL7033423 | 0.82 | TK1 (0.39) | TK1LMNAALBBLMTSHR | |
| SCHEMBL5698865 | 0.82 | TK1 (0.39) | TK1LMNAALBBLMTSHR | |
| SCHEMBL29088052 | 0.82 | TK1 (0.39) | TK1LMNAALBBLMTSHR | |
| SCHEMBL29763091 | 0.82 | TK1 (0.39) | TK1LMNAALBBLMTSHR | |
| SCHEMBL7027956 | 0.82 | TK1 (0.39) | TK1LMNAALBBLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032446-A1 | GAPPED 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060270624-A1 | GAPPED 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1695979-A2 | Gapped 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1044987-B1 | Gapped 2'-modified oligonucleotides | ISIS PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050112563-A9 | Gapped 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20040038274-A1 | Gapped 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20020160379-A1 | Gapped 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6326199-B1 | Gapped 2′ modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
| EP-0618925-B1 | ANTISENSE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6146829-A | MODIFYING RNA IN TEST SOLUTION CONTAINING RNASE HI BY HYBRIDIZING WITH OLIGONUCLEOTIDE HAVING NUCLEOTIDES WITH 2'DEOXY-ERYTHRO-PENTOFURANOSYL SUGAR MOIETIES; ACTIVATES RNASE AND RESISTS NUCLEASE DEGRADATION | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-1044987-A2 | Gapped 2'-modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-5856455-A | INCREASED NUCLEASE RESISTANCE; ATLEAST ONE NUCLEOTIDE UNIT BEARS AMINOALKOXY, ALLYLOXY, OR IMIDAZOLYLALKOXY 2'-SUBSTITUENT GROUP AND PLURITY OF NUCLEOTIDE GROUP HAVE 2'-DEOXY-ERYTHROPENTOFURANOSYL SUGAR UNITS | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5623065-A | MODIFIED OLIGONUCLEOTIDE WHICH HAS BINDING AFFINITY TO COMPLEMENTARY NUCLEIC ACID, INHIBITS TRANSLOCATION OF SAID ACID, PROMOTES RIBONUCLEASE CLEAVAGE IN VITRO | ISIS PHARMACEUTICALS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0618925-A4 | GAPPED 2' MODIFIED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1997-01-02 | — | — | EP | disclosed |
| EP-0618925-A1 | GAPPED 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013121-A1 | GAPPED 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |